BioLineRx’s Aphexda approved to aid stem cell transplants for multiple myeloma patients
Autologous stem cell transplantation (ASCT) is part of the standard of care for patients with multiple myeloma. It’s a process in which a patient’s own stem cells are removed and reintroduced, often after treatment with chemotherapy. But some patients don’t make good candidates.
Less than half of patients have had trouble collecting target numbers of hematopoietic stem cells in one round, depending on other factors, according to Tel Aviv-based biotech BioLineRx. The company hopes to change that with its newly approved therapy: Aphexda, also known as motixafortide.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.